Patents by Inventor Constance Neely

Constance Neely has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20070269847
    Abstract: Subjects at risk for developing cancer may be identified by obtaining samples of diagnostic cells from the subjects and determining a measure of cytotoxicity of the cells, the measure of cytotoxicity correlating negatively with the risk of developing cancer. The development of cancer may be prevented in subjects determined to be at risk for developing cancer by administering priming and activating agents to the subject, by increasing the expression of A1 adenosine receptors in cells of the subject, and increasing the affinity of cells of the subject for A1 adenosine receptor ligands. The preventative and diagnostic methods of the present invention may be carried out with kits and pharmaceutical liposomal formulations.
    Type: Application
    Filed: June 29, 2007
    Publication date: November 22, 2007
    Applicant: Endacea, Inc.
    Inventor: Constance Neely
  • Patent number: 6680052
    Abstract: Methods of treating and/or imaging tumors utilize A1 adenosine-receptor activated cells (such as monocytes and macrophages) are described. Activated cells may be administered systemically or locally, and may be radiolabelled to provide imaging and diagnostic functions. Macrophages resident in tissues may be primed and activated for use in treating and imaging tumors.
    Type: Grant
    Filed: December 16, 1999
    Date of Patent: January 20, 2004
    Assignee: Endacea, Inc.
    Inventor: Constance Neely
  • Publication number: 20030129678
    Abstract: Subjects at risk for developing cancer may be identified by obtaining samples of diagnostic cells from the subjects and determining a measure of cytotoxicity of the cells, the measure of cytotoxicity correlating negatively with the risk of developing cancer. The development of cancer may be prevented in subjects determined to be at risk for developing cancer by administering priming and activating agents to the subject, by increasing the expression of A1 adenosine receptors in cells of the subject, and increasing the affinity of cells of the subject for A1 adenosine receptor ligands. The preventative and diagnostic methods of the present invention may be carried out with kits and pharmaceutical liposomal formulations.
    Type: Application
    Filed: December 11, 2002
    Publication date: July 10, 2003
    Inventor: Constance Neely
  • Patent number: 6495687
    Abstract: A compound useful as an A1 adenosine receptor antagonist has the formula: wherein R1 is selected from the group consisting of C1-C8 alkyl; R2 is of the formula: R3 is of the formula: —(CH2)qC6H4—R7 R4 is of the formula:
    Type: Grant
    Filed: May 3, 2000
    Date of Patent: December 17, 2002
    Assignee: Endacea, Inc.
    Inventor: Constance Neely
  • Patent number: 6159701
    Abstract: Methods of treating and/or imaging tumors utilize A.sub.1 adenosine-receptor activated cells (such as monocytes and macrophages) are described. Activated cells may be administered systemically or locally, and may be radiolabelled to provide imaging and diagnostic functions. Macrophages resident in tissues may be primed and activated for use in treating and imaging tumors.
    Type: Grant
    Filed: November 8, 1996
    Date of Patent: December 12, 2000
    Assignee: Link Technology Incorporated
    Inventor: Constance Neely
  • Patent number: 6117998
    Abstract: A compound useful as an A.sub.1 adenosine receptor antagonist has the formula: ##STR1## wherein R.sub.1 is selected from the group consisting of C.sub.1 -C.sub.8 alkyl;R.sub.2 is of the formula: ##STR2## wherein n is an integer ranging from 1 to 8; R.sub.5 is H or (CH.sub.2).sub.p, wherein p is an integer ranging from 1 to 8; and R.sub.6 is H or (CH.sub.2).sub.m OH, wherein m is an integer ranging from 1 to 8;R.sub.3 is of the formula:--(CH.sub.2).sub.q C.sub.6 H.sub.4 --R.sub.7wherein q is an integer ranging from 1 to 8; and wherein R.sub.7 is selected from the group consisting of H, NH.sub.2, (CH.sub.2).sub.t OH, wherein t is an integer ranging from 1 to 8; and R.sub.9 COOH, wherein R.sub.9 is an alkyl or alkylidene group having 1 to 8 carbon atoms; andR.sub.4 is of the formula: ##STR3## wherein R.sub.8 is selected from the group consisting of H; NH.sub.2 ; (CH.sub.2).sub.s OH, wherein s is an integer ranging from 1 to 8; and R.sub.10 COOH, wherein R.sub.
    Type: Grant
    Filed: April 15, 1998
    Date of Patent: September 12, 2000
    Assignee: Link Technology Incorporated
    Inventor: Constance Neely
  • Patent number: 5786360
    Abstract: A compound useful as an A.sub.1 adenosine receptor antagonist has the formula: ##STR1## wherein R.sub.1 is selected from the group consisting of C.sub.1 -C.sub.8 alkyl;R.sub.2 is of the formula: ##STR2## wherein n is an integer ranging from 1 to 8; R.sub.5 is H or (CH.sub.2).sub.p, wherein p is an integer ranging from 1 to 8; and R.sub.6 is H or (CH.sub.2).sub.m OH, wherein m is an integer ranging from 1 to 8;R.sub.3 is of the formula:--(CH.sub.2).sub.q C.sub.6 H.sub.4 --R.sub.7wherein q is an integer ranging from 1 to 8; and wherein R.sub.7 is selected from the group consisting of H, NH.sub.2, (CH.sub.2).sub.t OH, wherein t is an integer ranging from 1 to 8; and R.sub.9 COOH, wherein R.sub.9 is an alkyl or alkylidene group having 1 to 8 carbon atoms; andR.sub.4 is of the formula: ##STR3## wherein R.sub.8 is selected from the group consisting of H; NH.sub.2 ; (CH.sub.2).sub.t OH, wherein s is an integer ranging from 1 to 8; and R.sub.10 COOH, wherein R.sub.
    Type: Grant
    Filed: November 19, 1996
    Date of Patent: July 28, 1998
    Assignee: Link Technology Incorporated
    Inventor: Constance Neely